Breast tumour heterogeneity
Breast cancers (as most solid cancers) have proven to be heterogeneous, i.e. consisting of several subclones that are genetically different. In collaboration with the Sanger Institute, we have performed several studies mapping the heterogeneity and evolution of subclones in early and late breast cancer. Currently, we are heading an EU-project (Transcan2) where subclonality of breast cancers that are in the early metastatic phase is assessed.
Key publications: Yates et al Nature Med., 2015